Franklin Resources’s iBio IBIO Stock Holding History

Franklin Resources’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-141	Closed	-$39K	–	2484
2021 Q4	$39K	Hold	141	–	–	﹤0.01%	2409
2021 Q3	$75K	Buy	+141	New	+$87.8K	﹤0.01%	2351

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources's IBIO Position: Q1 2022 in Review

Franklin Resources sold out of iBio (IBIO) in Q1 2022, closing a stake of 141 shares — an estimated $39K sold.

Franklin Resources first reported a position in IBIO in Q3 2021 and held it in 2 quarters. The position peaked at $75K in Q3 2021. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

Franklin Resources reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
Franklin Resources sold 141 iBio shares in Q1 2022, an estimated $39K.
Franklin Resources first reported a position in iBio in Q3 2021 and held it in 2 quarters.
Franklin Resources's iBio position peaked at $75K in Q3 2021.
70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Franklin Resources's 13F filing for Q1 2022, filed 13 May 2022.